Back

Visualizing reactive astrogliosis extends survival in glioblastoma patients

Ko, H. Y.; Chung, J.-I.; Kim, D.; Park, Y. M.; Jo, H. H.; Lee, S.; Kim, S. Y.; Kim, J.; Chun, J.-H.; Han, K.-S.; Lee, M.; Ju, Y.; Park, S. J.; Park, K. D.; Nam, M.-H.; Kim, S. H.; Chang, J. H.; Lee, C. J.; Yun, M.

2021-04-14 cancer biology
10.1101/2021.04.13.439750 bioRxiv
Show abstract

Glioblastoma multiforme (GBM) is a devastating brain tumor with dismal prognosis of only 15-month survival regardless of surgical resection. Here, we report an advanced neuroimaging technique combining 11C-acetate PET and MRI (AcePET), visualizing the boundary beyond the MRI-defined tumor. Targeted biopsy of the regions with increased 11C-acetate uptake revealed the presence of reactive astrocytes with enhanced acetate-transporter MCT1, along with cancer stem cells. Reactive astrogliosis and MCT1-dependent 11C-acetate-uptake were recapitulated in U87MG-orthotopic models. Mechanistically, glycolytic tumor cells release excessive acetate causing reactive astrogliosis, leading to the release of aberrant astrocytic GABA and H2O2, which further down-regulate the neuronal glucose uptake through GLUT3. Clincally, AcePET-guided surgery allows complete tumor resection of infiltrating cancer stem cells and extends the overall survival of patients by 5.25 months compared to conventional MRI-guided surgery. We established a new concept of the metabolic interactions between GBM cells and neighboring neurons through reactive astrocytes and developed AcePET-guided surgery to fight against GBM.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.